CoChat
Sign Up
Cited by 534Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

Open access
Tufail, Muhammad, Jiang, Can-Hua, Li, Ning·2024·Molecular Cancer
DOI 10.1186/s12943-024-02119-3PMC PMC11409553
Open this paper in CoChat — free accountOpen PDF

Abstract

Cancer cells undergo significant metabolic reprogramming to support their rapid growth and survival. This study examines important metabolic pathways like glycolysis, oxidative phosphorylation, glutaminolysis, and lipid metabolism, focusing on how they are regulated and their contributions to the development of tumors. The interplay between oncogenes, tumor suppressors, epigenetic modifications, and the tumor microenvironment in modulating these pathways is examined. Furthermore, we discuss the therapeutic potential of targeting cancer metabolism, presenting inhibitors of glycolysis, glutaminolysis, the TCA cycle, fatty acid oxidation, LDH, and glucose transport, alongside emerging strategies targeting oxidative phosphorylation and lipid synthesis. Despite the promise, challenges such as metabolic plasticity and the need for combination therapies and robust biomarkers persist, underscoring the necessity for continued research in this dynamic field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-024-02119-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 262

  1. [1]Sedeta E, Sung H, Laversanne M, Bray F, Jemal A. Recent mortality patterns and time trends for the major cancers in 47 countries worldwide. Cancer Epidemiol Biomarkers Prev. 2023;32:894–905. 37195435 · DOI
  2. [2]Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47–53. 39036382 PMC11256708 · DOI
  3. [3]Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13:10. 38287402 PMC10826200 · DOI
  4. [4]Kim Y, Jang Y, Kim MS, Kang C. Metabolic remodeling in cancer and senescence and its therapeutic implications. Trends Endocrinol Metab. 2024;35:744. 38453603 · DOI
  5. [5]Akter R, Awais M, Boopathi V, Ahn JC, Yang DC, Kang SC, Yang DU, Jung S-K. Inversion of the Warburg effect: unraveling the metabolic Nexus between obesity and cancer. ACS Pharmacol Trans Sci. 2024;7:560–9. PMC10928896 38481689 · DOI
  6. [6]Lam Wong KK, Verheyen EM. Metabolic reprogramming in cancer: mechanistic insights from Drosophila. Dis Models Mech. 2021;14:dmm048934. PMC8277969 34240146 · DOI
  7. [8]Liefwalker DF, Ryan M, Wang Z, Pathak KV, Plaisier S, Shah V, Babra B, Dewson GS, Lai IK, Mosley AR, et al. Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies. Cancer Metabolism. 2021;9:31. 34399819 PMC8369789 · DOI
  8. [9]Stein BD, Ferrarone JR, Gardner EE, Chang JW, Wu D, Hollstein PE, Liang RJ, Yuan M, Chen Q, Coukos JS, et al. LKB1-Dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma. Cancer Discov. 2023;13:1002–25. 36715544 PMC10068449 · DOI
  9. [10]Ciccarese F, Zulato E, Indraccolo S. LKB1/AMPK pathway and drug response in cancer: a therapeutic perspective. Oxidative Med Cell Longevity. 2019;2019:8730816. PMC6874879 31781355 · DOI
  10. [11]Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Investig. 2022;132:132. PMC9151701 35642641 · DOI
  11. [12]Mucaj V, Shay JES, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. 2012;95:464–70. 22539362 · DOI
  12. [13]Sadria M, Seo D, Layton AT. The mixed blessing of AMPK signaling in Cancer treatments. BMC Cancer. 2022;22:105. 35078427 PMC8786626 · DOI
  13. [14]Novikova DS, Garabadzhiu AV, Melino G, Barlev NA, Tribulovich VG. AMP-activated protein kinase: structure, function, and role in pathological processes. Biochem (Moscow). 2015;80:127–44. 25756529 · DOI
  14. [15]Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10:31. 32175074 PMC7063815 · DOI
  15. [16]Zhao H, Li Y. Cancer metabolism and intervention therapy. Mol Biomed. 2021;2:5. 35006438 PMC8607959 · DOI
  16. [17]Trajkovic-Arsic M, Subramani E. Is metabolism the magic bullet for targeted cancer therapy? BMC Cancer. 2023;23:484. 37254076 PMC10228052 · DOI
  17. [18]Huldani H, Malviya J, Rodrigues P, Hjazi A, Deorari MM, Al-Hetty HRAK, Qasim QA, Alasheqi MQ, Ihsan A. Discovering the strength of immunometabolism in cancer therapy: employing metabolic pathways to enhance immune responses. Cell Biochem Funct. 2024;42:e3934. 38379261 · DOI
  18. [19]Latham BD, Geffert RM, Jackson KD. Kinase inhibitors FDA approved 2018–2023: drug targets, metabolic pathways, and drug-induced toxicities. Drug Metab Dispos. 2024;52:479–92. 38286637 PMC11114602 · DOI
  19. [20]Nath S, Balling R. The Warburg effect reinterpreted 100 year on: a first-principles stoichiometric analysis and interpretation from the perspective of ATP metabolism in cancer cells. Function. 2024;5:zqae008. 38706962 PMC11065116 · DOI
  20. [22]Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett. 2012;4:1151–7. 23226794 PMC3506713 · DOI
  21. [23]Shiratori R, Furuichi K, Yamaguchi M, Miyazaki N, Aoki H, Chibana H, Ito K, Aoki S. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci Rep. 2019;9:18699. 31822748 PMC6904735 · DOI
  22. [24]Kim J-w, Dang CV. Cancer’s Molecular Sweet tooth and the Warburg Effect. Cancer Res. 2006;66:8927–30. 16982728 · DOI
  23. [25]Lv X-b, Liu L, Cheng C, Yu B, Xiong L, Hu K, Tang J, Zeng L, Sang Y. SUN2 exerts tumor suppressor functions by suppressing the Warburg effect in lung cancer. Sci Rep. 2015;5:17940. 26658802 PMC4674702 · DOI
  24. [26]Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ, et al. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935. 24343302 PMC3969270 · DOI · Paper page
  25. [27]Wang B, Pei J, Xu S, Liu J, Yu J. A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle. J Exp Clin Cancer Res. 2024;43:74. 38459595 PMC10921613 · DOI
  26. [28]Nguyen T-L, Durán RV. Glutamine metabolism in cancer therapy. Cancer Drug Resist. 2018;1:126–38.
  27. [29]Yoo HC, Yu YC, Sung Y, Han JM. Glutamine reliance in cell metabolism. Exp Mol Med. 2020;52:1496–516. 32943735 PMC8080614 · DOI · Paper page
  28. [30]Li T, Copeland C, Le A. Glutamine Metabolism in Cancer. In: Le A, editor. The Heterogeneity of Cancer Metabolism. Cham: Springer International Publishing; 2021. p. 17–38.
  29. [31]Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN. Synthetic lethality in cancer therapeutics: the next generation. Cancer Discov. 2021;11:1626–35. 33795234 PMC8295179 · DOI
  30. [32]Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transd Target Ther. 2020;5:241. PMC7573576 33077733 · DOI
  31. [33]Dalla Pozza E, Dando I, Pacchiana R, Liboi E, Scupoli MT, Donadelli M, Palmieri M. Regulation of succinate dehydrogenase and role of succinate in cancer. Semin Cell Dev Biol. 2020;98:4–14. 31039394 · DOI · Paper page
  32. [34]Aghamir SMK, Heshmat R, Ebrahimi M, Ketabchi SE, Parichehreh Dizaji S, Khatami F. The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review. Onco Targets Ther. 2019;12:7929–40. 31579262 PMC6771773 · DOI
  33. [35]Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021;13: 4184. 34439338 PMC8394807 · DOI
  34. [36]Sarkadi B, Meszaros K, Krencz I, Canu L, Krokker L, Zakarias S, Barna G, Sebestyen A, Papay J, Hujber Z, et al. Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas. Cancers (Basel). 2020;12:12. PMC7139890 32150977 · DOI · Paper page
  35. [37]Kitazawa S, Ebara S, Ando A, Baba Y, Satomi Y, Soga T, Hara T. Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors. Oncotarget. 2017;8:28922–38. 28423651 PMC5438703 · DOI
  36. [38]Valcarcel-Jimenez L, Frezza C. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism. Br J Cancer. 2023;129:1546–57. 37689804 PMC10645937 · DOI
  37. [39]Lindner AK, Tulchiner G, Seeber A, Siska PJ, Thurnher M, Pichler R. Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front Oncol. 2022;12:906014. 35912170 PMC9337267 · DOI
  38. [40]Ahmad IM, Dafferner AJ, Salloom RJ, Abdalla MY. Heme Oxygenase-1 Inhibition modulates autophagy and augments arsenic trioxide cytotoxicity in pancreatic cancer cells. Biomedicines. 2023;11:2580. 37761021 PMC10526552 · DOI
  39. [41]Romeo G, Ciaffaglione V, Amata E, Dichiara M, Calabrese L, Vanella L, Sorrenti V, Grosso S, D’Amico AG, D’Agata V, et al. Combination of Heme Oxygenase-1 inhibition and sigma receptor modulation for anticancer activity. Molecules. 2021;26:3860. 34202711 PMC8270315 · DOI
  40. [42]Parker SJ, Metallo CM. Metabolic consequences of oncogenic IDH mutations. Pharmacol Ther. 2015;152:54–62. 25956465 PMC4489982 · DOI
  41. [43]Hvinden IC, Cadoux-Hudson T, Schofield CJ, McCullagh JSO. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations. Cell Rep Med. 2021;2:100469. 35028610 PMC8714851 · DOI
  42. [44]Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, et al. Extreme vulnerability of IDH1 mutant cancers to NAD + depletion. Cancer Cell. 2015;28:773–84. 26678339 PMC4684594 · DOI · Paper page
  43. [45]Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 2015;28(6):773–84. 10.1016/j.ccell.2015.11.006. PMC4684594 26678339 · DOI · Paper page
  44. [46]Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, et al. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metab. 2018;6:4. 29692895 PMC5905129 · DOI
  45. [47]Marcucci F, Rumio C. On the role of Glycolysis in early tumorigenesis—permissive and Executioner effects. Cells. 2023;12: 1124. 37190033 PMC10137279 · DOI
  46. [48]Li C, Liu F-Y, Shen Y, Tian Y, Han F-J. Research progress on the mechanism of glycolysis in ovarian cancer. Front Immunol. 2023;14:1284853. 38090580 PMC10715264 · DOI
  47. [49]Nong S, Han X, Xiang Y, Qian Y, Wei Y, Zhang T, Tian K, Shen K, Yang J, Ma X. Metabolic reprogramming in cancer: mechanisms and therapeutics. MedComm. 2023;4:e218. 36994237 PMC10041388 · DOI
  48. [50]Yang F, Hilakivi-Clarke L, Shaha A, Wang Y, Wang X, Deng Y, Lai J, Kang N. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78:1602–24. 36626639 PMC10315435 · DOI
  49. [51]Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how many players are involved? J Cancer. 2017;8:3430–40. 29151926 PMC5687156 · DOI
  50. [52]Ganapathy-Kanniappan S, Geschwind J-FH. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. 24298908 PMC4223729 · DOI
  51. [53]Zhou Z, Li Y, Chen S, Xie Z, Du Y, Liu Y, Shi Y, Lin X, Zeng X, Zhao H, Chen G. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma. Cell Commun Signal. 2024;22:303. 38831321 PMC11145837 · DOI
  52. [56]Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, Sierpinski R, Majsterek I. PI3K/Akt/mTOR signaling pathway in blood malignancies-new therapeutic possibilities. Cancers (Basel). 2023;15:5297. 37958470 PMC10648005 · DOI
  53. [57]Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88. 31686003 PMC7314312 · DOI · Paper page
  54. [58]Deng H, Chen Y, Li P, Hang Q, Zhang P, Jin Y, Chen M. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: potential targets to overcome radioresistance in small cell lung cancer. Cancer Pathog Ther. 2023;1:56–66. 38328610 PMC10846321 · DOI
  55. [59]Chelakkot C, Chelakkot VS, Shin Y, Song K. Modulating glycolysis to improve cancer therapy. Int J Mol Sci. 2023;24:2606. 36768924 PMC9916680 · DOI
  56. [61]Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511. 31678210 · DOI
  57. [62]Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med. 2012;209:211–5. 22330683 PMC3280882 · DOI
  58. [63]Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24:2482–90. 29420223 · DOI
  59. [64]Qiu X, Li Y, Zhang Z. Crosstalk between oxidative phosphorylation and immune escape in cancer: a new concept of therapeutic targets selection. Cell Oncol. 2023;46:847–65. PMC12974702 37040057 · DOI
  60. [65]Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers. 2023;15:62. PMC9817696 36612059 · DOI
  61. [66]Chen C, Hao X, Lai X, Liu L, Zhu J, Shao H, Huang D, Gu H, Zhang T, Yu Z, et al. Oxidative phosphorylation enhances the leukemogenic capacity and resistance to chemotherapy of B cell acute lymphoblastic leukemia. Sci Adv. 2021;7:7. PMC7946372 33692103
  62. [67]de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36:1–12. 34561557 PMC8727299 · DOI
  63. [68]Peng M, Huang Y, Zhang L, Zhao X, Hou Y. Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells. Front Oncol. 2022;12:899502. 35574326 PMC9100571 · DOI
  64. [69]Nelson MAM, McLaughlin KL, Hagen JT, Coalson HS, Schmidt C, Kassai M, Kew KA, McClung JM, Neufer PD, Brophy P, et al. Intrinsic OXPHOS limitations underlie cellular bioenergetics in leukemia. eLife. 2021;10:e63104. 34132194 PMC8221809 · DOI
  65. [70]Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and Flexibility dynamics for Cancer Therapy. Cancer Discov. 2020;10:1797–807. 33139243 PMC7710573 · DOI
  66. [71]Grasmann G, Mondal A, Leithner K. Flexibility and adaptation of cancer cells in a heterogenous metabolic microenvironment. Int J Mol Sci. 2021;22:1476. 33540663 PMC7867260 · DOI
  67. [73]Ma Y, Wang L, Jia R. The role of mitochondrial dynamics in human cancers. Am J Cancer Res. 2020;10:1278–93. 32509379 PMC7269774
  68. [74]Chen W, Zhao H, Li Y. Mitochondrial dynamics in health and disease: mechanisms and potential targets. Signal Transd Target Ther. 2023;8:333. PMC10480456 37669960 · DOI · Paper page
  69. [75]Punter KB, Chu C, Chan EYW. Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer. Endocr Relat Cancer. 2023;30:e220229. 36356297 · DOI
  70. [76]Goda N, Kanai M. Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol. 2012;95:457–63. 22535382 · DOI
  71. [78]Elzakra N, Kim Y. HIF-1α Metabolic Pathways in Human Cancer. In: Hu S, editor. Cancer Metabolomics: Methods and Applications. Cham: Springer International Publishing; 2021. p. 243–60.
  72. [79]Sato T, Ichise N, Kobayashi T, Fusagawa H, Yamazaki H, Kudo T, Tohse N. Enhanced glucose metabolism through activation of HIF-1α covers the energy demand in a rat embryonic heart primordium after heartbeat initiation. Sci Rep. 2022;12:74. 34996938 PMC8741773 · DOI
  73. [80]Carroll VA, Ashcroft M. Role of Hypoxia-Inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF Target genes in response to Hypoxia, insulin-like Growth Factor-I, or loss of Von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 2006;66:6264–70. 16778202 · DOI
  74. [81]Song I-S, Wang A-G, Yoon SY, Kim J-M, Kim JH, Lee D-S, Kim N-S. Regulation of glucose metabolism-related genes and VEGF by HIF-1α and HIF-1β, but not HIF-2α, in gastric cancer. Exp Mol Med. 2009;41:51–8. 19287200 PMC2679279 · DOI
  75. [82]Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44:479–96. 20370557 PMC3880197 · DOI
  76. [84]Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B, Kumar D. Oxidative stress in cancer cell metabolism. Antioxidants. 2021;10(5):642. 33922139 PMC8143540 · DOI
  77. [86]Jing Q, Zhou C, Zhang J, Zhang P, Wu Y, Zhou J, Tong X, Li Y, Du J, Wang Y. Role of reactive oxygen species in myelodysplastic syndromes. Cell Mol Biol Lett. 2024;29:53. 38616283 PMC11017617 · DOI
  78. [87]Manoharan RR, Prasad A, Pospíšil P, Kzhyshkowska J. ROS signaling in innate immunity via oxidative protein modifications. Front Immunol. 2024;15:15. PMC10954773 38515749 · DOI
  79. [88]Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B, Cheng SY. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721–43. 32754274 PMC7392012 · DOI · Paper page
  80. [89]Zhou H-M, Zhang J-G, Zhang X, Li Q. Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transd Target Ther. 2021;6:62. PMC7884707 33589595 · DOI
  81. [90]Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodriguez-Arabaolaza I, Cordero-Barreal A, et al. Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy. J Exp Clin Cancer Res. 2024;43:33. 38281027 PMC10821268 · DOI
  82. [91]Jones CL, Inguva A, Jordan CT. Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors. Cell Stem Cell. 2021;28:378–93. 33667359 PMC7951949 · DOI
  83. [92]Beerkens APM, Boreel DF, Nathan JA, Neuzil J, Cheng G, Kalyanaraman B, Hardy M, Adema GJ, Heskamp S, Span PN, Bussink J. Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging. Cancer Metab. 2024;12:13. 38702787 PMC11067257 · DOI
  84. [93]Kosaisawe N, Sparta B, Pargett M, Teragawa CK, Albeck JG. Transient phases of OXPHOS inhibitor resistance reveal underlying metabolic heterogeneity in single cells. Cell Metab. 2021;33:649–e665648. 33561427 PMC8005262 · DOI
  85. [94]Janku F, Beom S-H, Moon YW, Kim TW, Shin YG, Yim D-S, Kim GM, Kim HS, Kim SY, Cheong J-H, et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investig New Drugs. 2022;40:1001–10. 35802288 PMC9395488 · DOI
  86. [95]Adamczuk G, Humeniuk E, Adamczuk K, Grabarska A, Dudka J. 2,4-Dinitrophenol as an uncoupler augments the anthracyclines toxicity against prostate cancer cells. Molecules. 2022;27:7227. 36364051 PMC9655928 · DOI
  87. [96]Bobba KN, Binoy A, Koo S, Nedungadi D, Podder A, Sharma A, Mishra N, Kim JS, Bhuniya S. Direct readout protonophore induced selective uncoupling and dysfunction of individual mitochondria within cancer cells. Chem Commun. 2019;55:6429–32. 31094377 · DOI
  88. [97]Rai Y, Singh S, Pandey S, Sah D, Sah RK, Roy BG, Dwarakanath BS, Bhatt AN. Mitochondrial uncoupler DNP induces coexistence of dual-state hyper-energy metabolism leading to tumor growth advantage in human glioma xenografts. Front Oncol. 2022;12:1063531. 36591481 PMC9800826 · DOI
  89. [98]Shrestha R, Johnson E, Byrne FL. Exploring the therapeutic potential of mitochondrial uncouplers in cancer. Mol Metab. 2021;51:101222. 33781939 PMC8129951 · DOI
  90. [99]Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35:3619–25. 26592449 PMC5225500 · DOI · Paper page
  91. [100]Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. Targeting glutaminolysis: New perspectives to understand Cancer Development and Novel strategies for potential target therapies. Front Oncol 2020, 10:589508. 33194749 PMC7649373 · DOI
  92. [102]Legendre F, MacLean A, Appanna VP, Appanna VD. Biochemical pathways to α-ketoglutarate, a multi-faceted metabolite. World J Microbiol Biotechnol. 2020;36:123. 32686016 · DOI
  93. [103]Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–34. 27492215 PMC5484415 · DOI · Paper page
  94. [104]Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43:2466–85. 25628363 PMC4344498 · DOI · Paper page
  95. [105]Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, Turay AM, Frauwirth KA. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185:1037–44. 20554958 PMC2897897 · DOI · Paper page
  96. [106]Jin J, Byun JK, Choi YK, Park KG. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55:706–15. 37009798 PMC10167356 · DOI
  97. [107]Choi YK, Park KG. Targeting glutamine metabolism for Cancer Treatment. Biomol Ther (Seoul). 2018;26:19–28. 29212303 PMC5746034 · DOI
  98. [108]Li X, Peng X, Li Y, Wei S, He G, Liu J, Li X, Yang S, Li D, Lin W, et al. Glutamine addiction in tumor cell: oncogene regulation and clinical treatment. Cell Communication Signal. 2024;22:12. 38172980 PMC10763057 · DOI
  99. [109]Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13:890–901. 24523301 · DOI · Paper page
  100. [110]Wicker CA, Hunt BG, Krishnan S, Aziz K, Parajuli S, Palackdharry S, Elaban WR, Wise-Draper TM, Mills GB, Waltz SE, Takiar V. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. Cancer Lett. 2021;502:180–8. 33450358 PMC7897292 · DOI
  101. [111]Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024;5:16–29. 38273023 · DOI
  102. [112]Wang W, Bai L, Li W, Cui J. The lipid metabolic landscape of cancers and new therapeutic perspectives. Front Oncol. 2020;10:605154. 33364199 PMC7753360 · DOI
  103. [113]Jeong D-W, Lee S, Chun Y-S. How cancer cells remodel lipid metabolism: strategies targeting transcription factors. Lipids Health Dis. 2021;20:163. 34775964 PMC8590761 · DOI
  104. [114]Wu Y, Pu X, Wang X, Xu M. Reprogramming of lipid metabolism in the tumor microenvironment: a strategy for tumor immunotherapy. Lipids Health Dis. 2024;23:35. 38302980 PMC10832245 · DOI
  105. [115]Simeone P, Tacconi S, Longo S, Lanuti P, Bravaccini S, Pirini F, Ravaioli S, Dini L, Giudetti AM. Expanding roles of de novo lipogenesis in breast cancer. Int J Environ Res Public Health. 2021;18(7):3575. 33808259 PMC8036647 · DOI
  106. [116]Mounier C, Bouraoui L, Rassart E. Lipogenesis in cancer progression (review). Int J Oncol. 2014;45:485–92. 24827738 · DOI
  107. [117]Lounis MA, Péant B, Leclerc-Desaulniers K, Ganguli D, Daneault C, Ruiz M, Zoubeidi A, Mes-Masson AM, Saad F. Modulation of de novo lipogenesis improves response to enzalutamide treatment in prostate cancer. Cancers. 2020;12:3339. 33187317 PMC7698241 · DOI
  108. [118]Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22. 31819192 PMC6964678 · DOI
  109. [119]Nagarajan SR, Butler LM, Hoy AJ. The diversity and breadth of cancer cell fatty acid metabolism. Cancer Metab. 2021;9:2. 33413672 PMC7791669 · DOI
  110. [120]Aoki T, Kinoshita J, Munesue S, Hamabe-Horiike T, Yamaguchi T, Nakamura Y, Okamoto K, Moriyama H, Nakamura K, Harada S, et al. Hypoxia-Induced CD36 expression in gastric Cancer cells promotes peritoneal metastasis via fatty acid uptake. Ann Surg Oncol. 2023;30:3125–36. 36042102 PMC10085939 · DOI
  111. [121]Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021;10(5):1056. 33946927 PMC8146072 · DOI
  112. [122]Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–62. 14585353 · DOI · Paper page
  113. [123]Corsetto PA, Zava S, Rizzo AM, Colombo I. The critical impact of sphingolipid metabolism in breast cancer progression and drug response. Int J Mol Sci. 2023;24:2107. 36768427 PMC9916652 · DOI
  114. [124]Wang Q, Zheng C, Hou H, Bao X, Tai H, Huang X, Li Z, Li Z, Wang Q, Pan Q. Interplay of Sphingolipid Metabolism in Predicting Prognosis of GBM patients: towards Precision Immunotherapy. J Cancer. 2024;15:275. 38164288 PMC10751665 · DOI
  115. [125]Alizadeh J, da Silva Rosa SC, Weng X, Jacobs J, Lorzadeh S, Ravandi A, Vitorino R, Pecic S, Zivkovic A, Stark H. Ceramides and ceramide synthases in cancer: focus on apoptosis and autophagy. Eur J Cell Biol. 2023;102:151337. 37392580 · DOI
  116. [126]Pilátová MB, Solárová Z, Mezencev R, Solár P. Ceramides and their roles in programmed cell death. Adv Med Sci. 2023;68:417–25. 37866204 · DOI
  117. [127]Qiao X, Hu Z, Xiong F, Yang Y, Peng C, Wang D, Li X. Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids Health Dis. 2023;22:45. 37004014 PMC10064535 · DOI
  118. [128]Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2020;218:e20201606. PMC7754673 33601415 · DOI
  119. [129]Zipinotti dos Santos D, de Souza JC, Pimenta TM, da Silva Martins B, Junior RSR, Butzene SMS, Tessarolo NG, Cilas PML, Silva IV, Rangel LBA. The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape. Cell Commun Signal. 2023;21:161. 37370164 PMC10304265 · DOI
  120. [130]Jin H-R, Wang J, Wang Z-J, Xi M-J, Xia B-H, Deng K, Yang J-L. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023;16:103. 37700339 PMC10498649 · DOI
  121. [131]Lasorsa F, di Meo NA, Rutigliano M, Ferro M, Terracciano D, Tataru OS, Battaglia M, Ditonno P, Lucarelli G. Emerging hallmarks of metabolic reprogramming in prostate cancer. Int J Mol Sci. 2023;24:910. 36674430 PMC9863674 · DOI
  122. [132]Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Reviews Endocrinol. 2024;20:93–110. 38049644 · DOI
  123. [133]Murali R, Balasubramaniam V, Srinivas S, Sundaram S, Venkatraman G, Warrier S, Dharmarajan A, Gandhirajan RK. Deregulated metabolic pathways in ovarian cancer: cause and consequence. Metabolites. 2023;13:560. 37110218 PMC10141515 · DOI
  124. [135]Elalfy MM, Elhadidy MG, El Nashar EM. Proto-oncogenes crosstalk, feedback and expression, and anticancer drugs resistance. Scientific Archives. 2023;5:18–21.
  125. [137]Gouw AM, Hsieh AL, Stine ZE, Dang CV. MYC Regulation of Metabolism and Cancer. In: Mazurek S, Shoshan M, editors. Tumor Cell Metabolism: Pathways, Regulation and Biology. Vienna: Springer Vienna; 2015. p. 101–22.
  126. [139]Wang W, Shi B, Cong R, Hao M, Peng Y, Yang H, Song J, Feng D, Zhang N, Li D. RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism. Cell Death Disc. 2022;8:372. PMC9402544 36002460 · DOI
  127. [140]Yu JSL, Cui W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development. 2016;143:3050–60. 27578176 · DOI
  128. [141]Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113. 38904014 PMC11186371 · DOI
  129. [142]Tufail M, Hu JJ, Liang J, He CY, Wan WD, Huang YQ, Jiang CH, Wu H, Li N. Hallmarks of cancer resistance. iScience. 2024;27:109979. 38832007 PMC11145355 · DOI
  130. [143]Gregory GL, Copple IM. Modulating the expression of tumor suppressor genes using activating oligonucleotide technologies as a therapeutic approach in cancer. Mol Therapy-Nucleic Acids. 2023;31:211–23. 36700046 PMC9840112 · DOI
  131. [145]Matoba S, Kang J-G, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006;312:1650–3. 16728594 · DOI · Paper page
  132. [146]Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis. Cell. 2006;126:107–20. 16839880 · DOI · Paper page
  133. [147]Keerthana CK, Rayginia TP, Shifana SC, Anto NP, Kalimuthu K, Isakov N, Anto RJ. The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. Front Immunol. 2023;14:1114582. 36875093 PMC9975160 · DOI
  134. [148]Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. Nat Rev Mol Cell Biol. 2023;24:255–72. 36316383 · DOI
  135. [150]Inoki K, Kim J, Guan K-L. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381–400. 22017684 · DOI
  136. [151]Shackelford DB, Shaw RJ. The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9:563–75. 19629071 PMC2756045 · DOI · Paper page
  137. [153]Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer. 2016;2:365–77. 27822561 PMC5096652 · DOI · Paper page
  138. [154]Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532–532. 23470539 PMC3613838 · DOI
  139. [155]Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251–62. 22436748 PMC5726489 · DOI · Paper page
  140. [156]Huo M, Zhang J, Huang W, Wang Y. Interplay among metabolism, epigenetic modifications, and Gene expression in Cancer. Front Cell Dev Biol. 2021;9:793428. 35004688 PMC8740611 · DOI
  141. [157]Xu X, Peng Q, Jiang X, Tan S, Yang Y, Yang W, Han Y, Chen Y, Oyang L, Lin J, et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med. 2023;55:1357–70. 37394582 PMC10394076 · DOI
  142. [158]Morrison AJ. Cancer cell metabolism connects epigenetic modifications to transcriptional regulation. FEBS J. 2022;289:1302–14. 34036737 PMC8613311 · DOI
  143. [159]Wang G, Han JJ. Connections between metabolism and epigenetic modifications in cancer. Med Rev. 2021;1:199–221. PMC10388788 37724300 · DOI
  144. [160]Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, He Y, Wu J, Zhang Z, Liu Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in Hepatoma cells. Mol Cancer Ther. 2011;10:1113–23. 21460102 · DOI
  145. [161]Ren J-H, He W-S, Nong L, Zhu Q-Y, Hu K, Zhang R-G, Huang L-L, Zhu F, Wu G. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharmaceut. 2010;25:75–80. 20187799 · DOI
  146. [162]Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:245. 31747960 PMC6868810 · DOI
  147. [163]Yang Y, Zhang M, Wang Y. The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy. J Natl Cancer Cent. 2022;2:277–90. 39036551 PMC11256729 · DOI
  148. [164]Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv Exp Med Biol. 2013;754:81–107. 22956497 · DOI
  149. [165]Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18:5–18. 29170536 PMC6337726 · DOI
  150. [166]Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51. 29570994 PMC6091663 · DOI · Paper page
  151. [167]Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13:239–50. 22436747 PMC4021399 · DOI · Paper page
  152. [168]Singh R, Yadav V, kumar S, Saini N. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep. 2015;5:17454. 26632252 PMC4668367 · DOI
  153. [169]Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63. 27070700 PMC4831138 · DOI
  154. [170]Xiao Y, Yu T-J, Xu Y, Ding R, Wang Y-P, Jiang Y-Z, Shao Z-M. Emerging therapies in cancer metabolism. Cell Metab. 2023;35:1283–303. 37557070 · DOI
  155. [171]Sedlak JC, Yilmaz ÖH, Roper J. Metabolism and colorectal cancer. Annu Rev Pathol. 2023;18:467–92. 36323004 PMC9877174 · DOI
  156. [172]Dong C, Yuan T, Wu Y, Wang Y, Fan TWM, Miriyala S, Lin Y, Yao J, Shi J, Kang T. Loss of FBP1 by snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 2013;23:316–31. 23453623 PMC3703516 · DOI
  157. [175]Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, Padilla PG, Ables G, Bamman MM, Thalacker-Mercer AE. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab. 2015;22:861–73. 26411344 PMC4635069 · DOI
  158. [176]Chen C, Wang Z, Qin Y. Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy. Front Pharmacol. 2022;13:13. PMC9354823 35935878
  159. [177]Thakur C, Chen F. Connections between metabolism and epigenetics in cancers. Semin Cancer Biol. 2019;57:52–8. 31185282 PMC6690786 · DOI
  160. [178]Ramalingam SS, Parise RA, Ramananthan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of Vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for Advanced Solid malignancies. Clin Cancer Res. 2007;13:3605–10. 17510206 · DOI
  161. [179]Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, et al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020;10:3080. 32080210 PMC7033174 · DOI
  162. [180]Chen JJ, Wang AQ, Chen QQ. DNA methylation assay for colorectal carcinoma. Cancer Biol Med. 2017;14:42–9. 28443202 PMC5365180 · DOI
  163. [181]Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121:809–18. 31607751 PMC6889302 · DOI
  164. [182]Heregger R, Huemer F, Steiner M, Gonzalez-Martinez A, Greil R, Weiss L. Unraveling resistance to Immunotherapy in MSI-High Colorectal Cancer. Cancers (Basel). 2023;15:15. PMC10605634 37894457 · DOI · Paper page
  165. [183]Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37. 24202395 PMC3954707 · DOI · Paper page
  166. [184]Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:1–11. 27515302 PMC4982339 · DOI · Paper page
  167. [185]Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–53. 25381661 PMC4264927 · DOI
  168. [186]Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98. 27550820 · DOI · Paper page
  169. [188]Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50. 29686425 PMC5998822 · DOI · Paper page
  170. [189]Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399–416. 28117416 PMC5480600 · DOI
  171. [190]Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. 31711497 PMC6844052 · DOI · Paper page
  172. [191]Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47–71. 23937437 · DOI
  173. [194]Klein K, He K, Younes AI, Barsoumian HB, Chen D, Ozgen T, Mosaffa S, Patel RR, Gu M, Novaes J, et al. Role of mitochondria in cancer immune evasion and potential therapeutic approaches. Front Immunol. 2020;11:11. 33178201 PMC7596324 · DOI
  174. [195]Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21–32. 33398194 PMC8097259 · DOI · Paper page
  175. [196]Chen X, Ma Z, Yi Z, Wu E, Shang Z, Tuo B, Li T, Liu X. The effects of metabolism on the immune microenvironment in colorectal cancer. Cell Death Disc. 2024;10:118. PMC10920911 38453888 · DOI
  176. [197]Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211–8. 26778478 PMC4783224 · DOI · Paper page
  177. [198]Pajak B, Siwiak E, Sołtyka M, Priebe A, Zieliński R, Fokt I, Ziemniak M, Jaśkiewicz A, Borowski R, Domoradzki T, Priebe W. 2-Deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents. Int J Mol Sci. 2019;21:234. 31905745 PMC6982256 · DOI
  178. [199]Singh R, Gupta V, Kumar A, Singh K. 2-Deoxy-D-glucose: a novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in covid-19, and other pharmacological activities. Adv Pharmacol Pharm Sci. 2023;2023:9993386. 36911357 PMC9998157
  179. [200]Bhutia YD, Babu E, Ganapathy V. Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine. Biochem J. 2016;473:1503–6. 27234586 PMC4888454 · DOI
  180. [201]Liu H, Kurtoglu M, León-Annicchiarico CL, Munoz-Pinedo C, Barredo J, Leclerc G, Merchan J, Liu X, Lampidis TJ. Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress. Oncotarget. 2016;7:36461–73. 27183907 PMC5095013 · DOI
  181. [202]Zielinski R, Castillo MM, Grybowski D, Grela K, Cardenas-Zuniga R, Fokt I, Skora S, Ramirez G, Priebe W. Abstract B179: 2-Deoxy-D-glucose (2-DG) combination with ketogenic diet induces sedation and hypothermia in mice that becomes lethal. Mol Cancer Ther. 2023;22:B179–179. · DOI
  182. [203]Ning SC, Hahn GM. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res. 1990;50:7867–70. 2253227
  183. [204]Orlovskiy S, Gupta PK, Roman J, Arias-Mendoza F, Nelson DS, Koch CJ, Narayan V, Putt ME, Nath K. Lonidamine induced selective acidification and De-energization of prostate cancer xenografts: enhanced tumor response to radiation therapy. Cancers. 2024;16:1384. 38611062 PMC11010960 · DOI
  184. [205]Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther. 2008;7:110–20. 18202014 · DOI
  185. [206]Emini Veseli B, Perrotta P, Van Wielendaele P, Lambeir AM, Abdali A, Bellosta S, Monaco G, Bultynck G, Martinet W, De Meyer GRY. Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3). FEBS Lett. 2020;594:3067–75. 32620030 · DOI
  186. [207]Kotowski K, Supplitt S, Wiczew D, Przystupski D, Bartosik W, Saczko J, Rossowska J, DrĄG-ZalesiŃSka M, Michel O, Kulbacka J. 3PO as a selective inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma cells. Anticancer Res. 2020;40:2613. 32366406 · DOI
  187. [208]Zahra K, Dey T, Ashish, Mishra SP, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159. 32195169 PMC7061896 · DOI
  188. [209]Dong G, Mao Q, Xia W, Xu Y, Wang J, Xu L, Jiang F. PKM2 and cancer: the function of PKM2 beyond glycolysis (review). Oncol Lett. 2016;11:1980–6. 26998110 PMC4774429 · DOI
  189. [210]Apostolidi M, Vathiotis IA, Muthusamy V, Gaule P, Gassaway BM, Rimm DL, Rinehart J. Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes. Cancer Res. 2021;81:4346–59. 34185676 PMC8373815 · DOI
  190. [211]Manerba M, Vettraino M, Fiume L, Di Stefano G, Sartini A, Giacomini E, Buonfiglio R, Roberti M, Recanatini M. Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase. ChemMedChem. 2012;7:311–7. 22052811 · DOI
  191. [212]Rellinger EJ, Craig BT, Alvarez AL, Dusek HL, Kim KW, Qiao J, Chung DH. FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery. 2017;161:747–52. 27919448 PMC5369647 · DOI
  192. [213]Han JH, Lee EJ, Park W, Ha KT, Chung HS. Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front Pharmacol. 2023;14:1275000. 37915411 PMC10616500 · DOI
  193. [214]Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–46. 16892078 · DOI
  194. [215]Zhao Y, Liu H, Liu Z, Ding Y, LeDoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al. Overcoming Trastuzumab resistance in breast Cancer by Targeting Dysregulated glucose metabolism. Cancer Res. 2011;71:4585–97. 21498634 PMC3129363 · DOI
  195. [216]Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Disc. 2022;21:141–62. PMC8641543 34862480 · DOI · Paper page
  196. [217]Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in Cancer: understanding the heterogeneity. Trends Cancer. 2017;3:169–80. 28393116 PMC5383348 · DOI · Paper page
  197. [218]Gong T, Zheng C, Ou X, Zheng J, Yu J, Chen S, Duan Y, Liu W. Glutamine metabolism in cancers: targeting the oxidative homeostasis. Front Oncol. 2022;12:994672. 36324588 PMC9621616 · DOI
  198. [219]Anthony J, Varalakshmi S, Sekar AK, Devarajan N, Janakiraman B, Peramaiyan R. Glutaminase - A potential target for cancer treatment. Biomed (Taipei). 2024;14:29–37. PMC11204126 38939098 · DOI
  199. [220]Xu L, Yin Y, Li Y, Chen X, Chang Y, Zhang H, Liu J, Beasley J, McCaw P, Zhang H, et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci. 2021;118:e2012748118. 33753479 PMC8020804 · DOI
  200. [221]Jin H, Wang S, Zaal EA, Wang C, Wu H, Bosma A, Jochems F, Isima N, Jin G, Lieftink C, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. eLife. 2020;9:e56749. 33016874 PMC7535927 · DOI

200 of 262 shown

Cited by

Sorted by citations

Authors
Tufail, M., Jiang, C.-H., & Li, N.
Affiliations
Central South University (CN)
Corresponding author
  • Tufail, Muhammad
  • Li, Ning
ORCID
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2024-09-18
Volume
23
Issue
1
Pages
203-203
ISSN
1476-4598 (ISSN-L)
DOI
10.1186/s12943-024-02119-3
PMC
PMC11409553
OpenAlex
W4402639721
Cited by
534
References
23
Citations by year
2026: 276 · 2025: 252 · 2024: 6
FWCI
26.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Cancer (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Sciences Foundation of China (82170974)
  • Central South University Research Program of Advanced Interdisciplinary Studies (2023QYJC038)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
cancer metabolism, metabolic reprogramming, glycolysis, oxidative phosphorylation, glutaminolysis, lipid metabolism, TCA cycle, fatty acid oxidation, lactate dehydrogenase, glucose transport, oncogenes, tumor suppressor, epigenetic modifications, tumor microenvironment, metabolic therapy, metabolic plasticity, combination therapy, biomarkers
MeSH terms
Animals, Antineoplastic Agents, Energy Metabolism, Glycolysis, Humans, Neoplasms, Oxidative Phosphorylation, Lipid Metabolism, Metabolic Networks and Pathways, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review